Origin and Mechanism of Action
All heparinoids are of biological origin. The primary source for industrial production is the porcine intestinal mucosa, from which the necessary sulfated glycosaminoglycans are extracted.
The mechanism of action of heparinoids is fundamentally similar to that of standard heparin. They do not possess direct intrinsic anticoagulant activity but act as potent catalysts. Heparinoids bind to antithrombin III (a natural anticoagulant) and vastly enhance its capacity to neutralize active factors of the coagulation cascade.
Despite this similarity, heparinoids are classified separately because their pharmacological profile, the ratio of inhibitory activity against various clotting factors, and their effects on blood cellular elements differ significantly from both unfractionated and low-molecular-weight heparins.
Sulodexide: Composition and Pleiotropic Effects
A primary representative of this group is sulodexide, a natural mixture of two glycosaminoglycans. The majority of its composition consists of heparan sulfate, with approximately 20% being dermatan sulfate.
Pharmacodynamically, sulodexide exhibits pronounced selectivity. It predominantly reduces the activity of factor Xa, whereas its inhibitory effect on thrombin (factor IIa) remains relatively weak.
A crucial feature of sulodexide is its additional (pleiotropic) effects, which significantly broaden its clinical applications:
- Angioprotective action: Effectively protects the vascular endothelium from damage.
- Increased fibrinolytic activity: Promotes the dissolution of formed fibrin strands.
- Hypolipidemic action: Positively influences lipid metabolism.
Due to this complex action, sulodexide is indicated for peripheral vascular diseases associated with a high thrombotic risk. It is also used for the prevention of pulmonary embolism (in the setting of deep vein thrombosis) and in secondary prevention of myocardial infarction.
Unlike many other anticoagulants, sulodexide is available in both parenteral formulations (for intravenous and intramuscular administration) and oral formulations. The main adverse effect requiring medical monitoring remains the risk of hemorrhagic complications.
Danaparoid Sodium and Managing Thrombocytopenia
The second key representative of the group is danaparoid sodium. Its composition is more complex, comprising a mixture of three components: heparan sulfate, dermatan sulfate, and chondroitin sulfate.
The pharmacodynamic profile of danaparoid sodium is also characterized by significantly stronger inhibition of factor Xa compared to thrombin suppression. The drug is administered subcutaneously and is widely used for both the prophylaxis and treatment of venous thrombosis.
A key advantage of danaparoid sodium, which radically distinguishes it from classical heparins, involves its interaction with blood cells. This drug does not bind to platelet factor 4. Consequently, it does not trigger a pathological immune response or cause severe heparin-induced thrombocytopenia (HIT).
This exact property dictates its primary clinical indication: danaparoid sodium serves as an absolute drug of choice when prior therapy with standard heparin is complicated by a drop in platelet count.